Monday, April 17, 2017 8:19:21 PM
OCRX Ocera Therapeutics...Apr. 17, 2017...OCRX has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure and acute-on-chronic liver disease.
Target $3...
OCRX... Ocera Therapeutics treatment of hyperammonemia and resultant hepatic encephalopathy
Target $3...
OCRX... Ocera Therapeutics treatment of hyperammonemia and resultant hepatic encephalopathy
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
